Skip to main content
Erschienen in: Cancer Causes & Control 10/2008

01.12.2008 | Original Paper

Hypercholesterolemia and prostate cancer: a hospital-based case–control study

verfasst von: Lindsay Magura, Richelle Blanchard, Brian Hope, James R. Beal, Gary G. Schwartz, Abe E. Sahmoun

Erschienen in: Cancer Causes & Control | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

High levels of serum cholesterol have been proposed to increase the risk of prostate cancer but the epidemiologic evidence is limited.

Methods

We conducted a hospital-based case–control study in Fargo, ND, USA, to examine the association between hypercholesterolemia and prostate cancer. Cases were men with incident, histologically confirmed prostate cancer. Controls were men without clinical cancer who were seen at the same hospital for an annual physical exam. Demographic and clinical data were abstracted from patients’ medical charts.

Results

From a patient population aged 50 to 74 years old, we obtained data on 312 White cases and 319 White controls. Hypercholesterolemia was defined as total cholesterol greater than 5.17 (mmol/l). Univariate logistic regression showed a significant association between hypercholesterolemia and prostate cancer (odds ratio (OR) = 1.64, 95% confidence interval (CI): 1.19–2.27). This association changed only slightly after adjustment for age, family history of prostate cancer, body mass index, type 2 diabetes, smoking, and multivitamin use (OR = 1.58, 95% CI: 1.11–2.24). A significant association was found between low HDL and prostate cancer (OR = 1.57, 95% CI: 1.04–2.36). High LDL was associated with a 60% increased risk for prostate cancer (OR = 1.60, 95% CI: 1.09–2.34). Compared to never smokers, current smokers had an 84% increased risk for prostate cancer (OR = 1.84, 95% CI: 1.09–3.13).

Conclusion

This study adds to recent evidence that hypercholesterolemia may increase the risk of prostate cancer in white men.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E et al (2008) Cancer Statistics. CA Cancer J Clin 58(2):73CrossRef Jemal A, Siegel R, Ward E et al (2008) Cancer Statistics. CA Cancer J Clin 58(2):73CrossRef
4.
Zurück zum Zitat Kirsh VA, Hayes RB, Mayne ST et al (2006) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98:245–254PubMed Kirsh VA, Hayes RB, Mayne ST et al (2006) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98:245–254PubMed
5.
Zurück zum Zitat Chen C, Lewis SK, Voigt L et al (2005) Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103:76–84. doi:10.1002/cncr.20727 PubMedCrossRef Chen C, Lewis SK, Voigt L et al (2005) Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103:76–84. doi:10.​1002/​cncr.​20727 PubMedCrossRef
6.
Zurück zum Zitat Giovannucci E, Rimm EB, Liu Y et al (2003) Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95:1240–1244PubMed Giovannucci E, Rimm EB, Liu Y et al (2003) Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95:1240–1244PubMed
7.
Zurück zum Zitat Swyer G (1942) The cholesterol content of normal and enlarged prostates. Cancer Res 2:372–375 Swyer G (1942) The cholesterol content of normal and enlarged prostates. Cancer Res 2:372–375
16.
19.
Zurück zum Zitat Platz EA, Leitzmann MF, Visvanathan K et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98:1819–1825PubMedCrossRef Platz EA, Leitzmann MF, Visvanathan K et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98:1819–1825PubMedCrossRef
22.
Zurück zum Zitat Bonovas S, Filioussi K, Sitaras NM (2008) Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123:899–904. doi:10.1002/ijc.23550 PubMedCrossRef Bonovas S, Filioussi K, Sitaras NM (2008) Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123:899–904. doi:10.​1002/​ijc.​23550 PubMedCrossRef
23.
Zurück zum Zitat Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 106:3143 Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 106:3143
25.
Zurück zum Zitat Sonnleithner M, Jeschke K, Bayer L et al (2003) Dyslipoproteinemia as a risk factor in prostate cancer. J Urol 169(4):76CrossRef Sonnleithner M, Jeschke K, Bayer L et al (2003) Dyslipoproteinemia as a risk factor in prostate cancer. J Urol 169(4):76CrossRef
26.
Zurück zum Zitat Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13(10):1646–1650PubMed Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13(10):1646–1650PubMed
29.
Zurück zum Zitat Hamalainen E, Adlercreutz H, Ehnholm C, Puska P (1986) Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 35(6):535–541. doi:10.1016/0026-0495(86)90011-9 PubMedCrossRef Hamalainen E, Adlercreutz H, Ehnholm C, Puska P (1986) Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 35(6):535–541. doi:10.​1016/​0026-0495(86)90011-9 PubMedCrossRef
31.
Zurück zum Zitat Shono N, Kumagai S, Higaki Y, Nishizumi M, Sasaki H (1996) The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. J Atheroscler Thromb 3(1):45–51PubMed Shono N, Kumagai S, Higaki Y, Nishizumi M, Sasaki H (1996) The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. J Atheroscler Thromb 3(1):45–51PubMed
33.
Zurück zum Zitat Key TJ, Allen N, Appleby P et al (2004) Fruits and vegetables and prostate cancer: no association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109(1):119–124. doi:10.1002/ijc.11671 PubMedCrossRef Key TJ, Allen N, Appleby P et al (2004) Fruits and vegetables and prostate cancer: no association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109(1):119–124. doi:10.​1002/​ijc.​11671 PubMedCrossRef
34.
Zurück zum Zitat Stram DO, Hankin JH, Wilkens LR et al (2006) Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study. Cancer Causes Control 17(9):1193–1207. doi:10.1007/s10552-006-0064-0 PubMedCrossRef Stram DO, Hankin JH, Wilkens LR et al (2006) Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study. Cancer Causes Control 17(9):1193–1207. doi:10.​1007/​s10552-006-0064-0 PubMedCrossRef
38.
Zurück zum Zitat Lawson KA, Wright ME, Subar A et al (2007) Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99(10):754–764. doi:10.1093/jnci/djk177 PubMedCrossRef Lawson KA, Wright ME, Subar A et al (2007) Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99(10):754–764. doi:10.​1093/​jnci/​djk177 PubMedCrossRef
42.
Zurück zum Zitat Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8(10):887–892PubMed Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8(10):887–892PubMed
43.
Zurück zum Zitat Drasch G, Schopfer J, Schrauzer GN (2005) Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium. Biol Trace Elem Res 103(2):103–107. doi:10.1385/BTER:103:2:103 PubMedCrossRef Drasch G, Schopfer J, Schrauzer GN (2005) Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium. Biol Trace Elem Res 103(2):103–107. doi:10.​1385/​BTER:​103:​2:​103 PubMedCrossRef
44.
Zurück zum Zitat Rohan TE, Hislop TG, Howe GR, Gallagher RP, Teh CZ, Ghadirian P (1997) Cigarette smoking and risk of prostate cancer: a population-based case–control study in Ontario and British Columbia, Canada. Eur J Cancer Prev 6(4):382–388. doi:10.1097/00008469-199708000-00011 PubMedCrossRef Rohan TE, Hislop TG, Howe GR, Gallagher RP, Teh CZ, Ghadirian P (1997) Cigarette smoking and risk of prostate cancer: a population-based case–control study in Ontario and British Columbia, Canada. Eur J Cancer Prev 6(4):382–388. doi:10.​1097/​00008469-199708000-00011 PubMedCrossRef
45.
Zurück zum Zitat Singal V, Khurana V, Caldito G, Fort C (2005) Statins and prostate cancer risk: a large case–control study in Veterans. J Clin Oncol 23:107S Singal V, Khurana V, Caldito G, Fort C (2005) Statins and prostate cancer risk: a large case–control study in Veterans. J Clin Oncol 23:107S
46.
Zurück zum Zitat Kaplan SA, Meehan AG, Shah A (2006) The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 176(4 Pt 1):1524–1527. doi:10.1016/j.juro.2006.06.003 PubMedCrossRef Kaplan SA, Meehan AG, Shah A (2006) The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 176(4 Pt 1):1524–1527. doi:10.​1016/​j.​juro.​2006.​06.​003 PubMedCrossRef
47.
Zurück zum Zitat Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51(14):3748–3752PubMed Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51(14):3748–3752PubMed
51.
Zurück zum Zitat Moorjani S, Dupont A, Labrie F et al (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 66(2):314–322PubMedCrossRef Moorjani S, Dupont A, Labrie F et al (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 66(2):314–322PubMedCrossRef
Metadaten
Titel
Hypercholesterolemia and prostate cancer: a hospital-based case–control study
verfasst von
Lindsay Magura
Richelle Blanchard
Brian Hope
James R. Beal
Gary G. Schwartz
Abe E. Sahmoun
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 10/2008
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9197-7

Weitere Artikel der Ausgabe 10/2008

Cancer Causes & Control 10/2008 Zur Ausgabe

Letter to the Editor

Prostate cancer screening

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.